Transcode Therapeutics (RNAZ) Cash from Investing Activities (2021 - 2024)
Transcode Therapeutics' (RNAZ) quarterly Cash from Investing Activities came in at -$500.0 in Q4 2024, up 96.11% on a QoQ basis from -$12870.0 in Q3 2024.
Transcode Therapeutics (RNAZ) Cash from Investing Activities (2021 - 2024) Analysis & Trends
Transcode Therapeutics (RNAZ) has 4 years of Cash from Investing Activities data on file, last reported at -$500.0 in Q4 2024.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$500.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$21761.0 (up 38.89% YoY) and the FY2025 annual result came in at -$4436.0, up 79.61% from the prior year.
- Cash from Investing Activities improved to -$500.0 in Q4 2024, from -$12870.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$500.0 in Q4 2024 to a low of -$82728.0 in Q4 2021.
- A 4-year average of -$29293.5 and a median of -$20173.5 in 2021 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 74.84% in 2024, down 179.42% in 2024.
- Tracing RNAZ's Cash from Investing Activities over 4 years: stood at -$82728.0 in 2021, then jumped by 65.89% to -$28215.0 in 2022, then soared by 83.68% to -$4606.0 in 2023, then jumped by 89.14% to -$500.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$500.0 (Q4 2024), -$12870.0 (Q3 2024), and -$4555.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -500.00 |
| Dec 31, 2024 | -500.00 |
| Sep 30, 2024 | -12,870.00 |
| Sep 30, 2024 | -12,870.00 |
| Jun 30, 2024 | -4,555.00 |
| Jun 30, 2024 | -4,555.00 |
| Mar 31, 2024 | -3,836.00 |
| Mar 31, 2024 | -3,836.00 |
| Sep 30, 2023 | -4,606.00 |
| Sep 30, 2023 | -4,606.00 |
| Jun 30, 2023 | -18,107.00 |
| Jun 30, 2023 | -18,107.00 |
| Mar 31, 2023 | -12,896.00 |
| Mar 31, 2023 | -12,896.00 |
| Dec 31, 2022 | -28,215.00 |
| Dec 31, 2022 | -28,215.00 |
| Jun 30, 2022 | -42,047.00 |
| Jun 30, 2022 | -42,047.00 |
| Mar 31, 2022 | -30,657.00 |
| Mar 31, 2022 | -30,657.00 |